AnYxis — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

AnYxis is an early-stage, privately held biopharma based in Vienna, Austria, operating in the high-growth sectors of vaccines, antibody therapies, and immuno-oncology. Founded in 2020, the company is in a pre-clinical or early clinical development stage, building a pipeline of biologic candidates. As a pre-revenue entity, its success hinges on advancing its research, securing strategic partnerships, and attracting further investment to fund costly clinical trials.

OncologyInfectious Diseases

Technology Platform

Platform details not publicly disclosed. Inferred focus on immunogen design, protein/antibody engineering, and immuno-oncology pathway modulation for developing vaccines, antibody therapies, and immuno-oncological treatments.

Opportunities

The company operates in massive, high-growth markets including immuno-oncology, therapeutic antibodies, and next-generation vaccines.

Its integrated focus on immunology across disease areas could enable synergistic platform insights and a diversified pipeline.

Being based in Austria provides access to EU scientific networks and non-dilutive grant funding.

Risk Factors

As an early-stage, pre-revenue private company, AnYxis faces high scientific risk of clinical failure, financial risk from dependence on external funding in a tight capital market, and intense competition in its core therapeutic areas.

The lack of public data on its pipeline, platform, and team adds significant uncertainty.

Competitive Landscape

AnYxis competes in the highly crowded and well-funded fields of immuno-oncology and antibody therapeutics, facing off against global pharmaceutical giants and numerous agile biotech companies. In vaccines, it competes with established players and novel platform companies (e.g., mRNA). Differentiation will require demonstrating superior efficacy, safety, or novel mechanisms of action.

More companies in Biologics / Biosimilars →More companies in Austria →